EXONATE LIMITED
Pharmaceutical ManufacturingEngland, United Kingdom11-50 Employees
Exonate Limited is a biotechnology company focused on developing non-invasive, small-molecule treatments for retinal vascular diseases that can lead to vision loss. Its lead asset, EXN407, is being investigated as a potential topical therapy for conditions such as diabetic retinopathy and diabetic macular edema, with prior trial results showing endpoints reached and encouraging efficacy signals in diabetic eye disease. The firm operates within the pharmaceutical manufacturing and biotechnology sector, targeting patients with retinal vascular diseases and aiming to provide non-invasive treatment options that address vision-threatening conditions. Based in Duxford, England, Exonate has a modest, specialist footprint and has engaged in partnerships and board-level expansions to advance its development program. A recent leadership appointment and ongoing Phase IIb activity indicate the company’s progression toward broader clinical evaluation of its lead candidate.
1-888-653-2347 
support@leadiq.com 
